Sonnet Bio Therapeutics
Biotechnology, 100 Overlook CTR Ste 102, Princeton, New Jersey, 08540, United States, 11-50 Employees
Who is SONNET BIOTHERAPEUTICS
As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. C...
Read More
-
Headquarters: 100 Overlook CTR Ste 102, Princeton, New Jersey, 08540, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from SONNET BIOTHERAPEUTICS
Sonnet BioTherapeutics Org Chart and Mapping
Email
Phone
Similar Companies to Sonnet BioTherapeutics
Azurity Pharmaceuticals
-
501-1000
-
$ 50 Million to 100 Million
Outlook Therapeutics, Inc.
-
10001+
-
$ 10 Million to 25 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Sonnet BioTherapeutics
Answer: Sonnet BioTherapeutics's headquarters are located at 100 Overlook CTR Ste 102, Princeton, New Jersey, 08540, United States
Answer: Sonnet BioTherapeutics's official website is https://sonnetbio.com
Answer: Sonnet BioTherapeutics's revenue is $1 Million to $5 Million
Answer: Sonnet BioTherapeutics's SIC: 2836
Answer: Sonnet BioTherapeutics's NAICS: 541714
Answer: Sonnet BioTherapeutics has 11-50 employees
Answer: Sonnet BioTherapeutics is in Biotechnology
Answer: Sonnet BioTherapeutics top competitors include: Azurity Pharmaceuticals , Outlook Therapeutics, Inc
Answer: Sonnet BioTherapeutics contact info: Phone number: Website: https://sonnetbio.com
Answer: As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnets proprietary FHABTM (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHABTM platform utilizes a fully human single chain antibody fragment (scFv) that binds to and hitchhikes on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnets FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process. (NASDAQ: SONN)
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month